Indeed, given that localised and metastatic tissues express alternative UGT2B17 mRNAs and no v1, combined with rising levels of UGT2B17 with increasing AR levels in primary tumours, it raises concerns about whether LNCaP constitutes an appropriate model to further study the UGT2B17_n2 and _n3 regulation observed in PCa. The gene discussed is UGT2B17; the disease is posterior cortical atrophy.